DROTRECOGIN ALFA | ScienceGate

Orphan designation: drotrecogin alfa (activated), Treatment of acute respiratory distress syndrome (ARDS)

Case Medical Research ◽

10.31525/cmr-21bf3e6 ◽

2019 ◽

Author(s):

Keyword(s):

Acute Respiratory Distress Syndrome ◽

Respiratory Distress Syndrome ◽

Respiratory Distress ◽

Drotrecogin Alfa ◽

Distress Syndrome ◽

Orphan Designation ◽

Drotrecogin Alfa Activated

Download Full-text

Faculty Opinions recommendation of Effects of drotrecogin alfa activated on microcirculatory alterations in patients with severe sepsis.

Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature ◽

10.3410/f.14700.472217 ◽

2006 ◽

Author(s):

Herwig Gerlach

Keyword(s):

Severe Sepsis ◽

Drotrecogin Alfa ◽

Drotrecogin Alfa Activated

Download Full-text

Faculty Opinions recommendation of Drotrecogin alfa (activated) in adults with septic shock.

Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature ◽

10.3410/f.717698023.793153132 ◽

2012 ◽

Author(s):

Daniel Remick

Keyword(s):

Septic Shock ◽

Drotrecogin Alfa ◽

Drotrecogin Alfa Activated

Download Full-text

Errors in the approval process and post-marketing evaluation of drotrecogin alfa (activated) for the treatment of severe sepsis

The Lancet Infectious Diseases ◽

10.1016/s1473-3099(08)70306-2 ◽

2009 ◽

Vol 9 (1) ◽

pp. 67-72 ◽

Cited By ~ 14

Author(s):

Daniele Poole ◽

Guido Bertolini ◽

Silvio Garattini

Keyword(s):

Severe Sepsis ◽

Drotrecogin Alfa ◽

Approval Process ◽

Drotrecogin Alfa Activated ◽

Post Marketing

Download Full-text

Drotrecogin alfa (activated) inhibits NF-kappa B activation and MIP-1-alpha release from isolated mononuclear cells of patients with severe sepsis

Inflammation Research ◽

10.1007/s00011-004-1291-z ◽

2004 ◽

Vol 53 (10) ◽

pp. 528-533 ◽

Cited By ~ 20

Author(s):

M. Brueckmann ◽

U. Hoffmann ◽

E. Dvortsak ◽

S. Lang ◽

J. J. Kaden ◽

...

Keyword(s):

Severe Sepsis ◽

Drotrecogin Alfa ◽

Mononuclear Cells ◽

Nf Kappa B ◽

Drotrecogin Alfa Activated

Download Full-text

TREATMENT OF CRITICALLY INJURED BURN PATIENTS WITH DROTRECOGIN ALFA: EXPERIENCE WITH ELEVEN BURN INTENSIVE CARE UNIT PATIENTS

Critical Care Medicine ◽

10.1097/00003246-200412001-00520 ◽

2004 ◽

Vol 32 (Supplement) ◽

pp. A146

Author(s):

Carla C Braxton ◽

Brian Hirsch ◽

Michael Moncure

Keyword(s):

Intensive Care Unit ◽

Intensive Care ◽

Drotrecogin Alfa ◽

Burn Patients

Download Full-text

Extended drotrecogin alfa (activated) therapy in patients with persistent requirement for vasopressor support after 96-hour infusion with commercial drotrecogin alfa (activated)

Critical Care ◽

10.1186/cc6426 ◽

2008 ◽

Vol 12 (Suppl 2) ◽

pp. P205 ◽

Cited By ~ 2

Author(s):

J Dhainaut ◽

M Antonelli ◽

P Wright ◽

M Belger ◽

M Cobas-Meyer ◽

...

Keyword(s):

Drotrecogin Alfa ◽

Vasopressor Support ◽

Drotrecogin Alfa Activated

Download Full-text

Drotrecogin alfa (activated): the treatment for severe sepsis?

Expert Opinion on Biological Therapy ◽

10.1517/14712598.7.11.1763 ◽

2007 ◽

Vol 7 (11) ◽

pp. 1763-1777 ◽

Cited By ~ 7

Author(s):

Jean-Louis Vincent

Keyword(s):

Severe Sepsis ◽

Drotrecogin Alfa ◽

Drotrecogin Alfa Activated

Download Full-text

PIN18 HOSPITAL LENGTH-OF-STAYAND COSTS ASSOCIATED WITH USE AND EARLIER INITIATION OF DROTRECOGIN ALFA (ACTIVATED) IN ADULT PATIENTS WITH THE HIGHEST PROPENSITY OF HAVING SEVERE SEPSIS

Value in Health ◽

10.1016/s1098-3015(10)64794-8 ◽

2006 ◽

Vol 9 (3) ◽

pp. A159

Author(s):

FR Ernst ◽

S Viswanathan ◽

G Vedarajan ◽

J Reynolds ◽

B Kohli

Keyword(s):

Severe Sepsis ◽

Drotrecogin Alfa ◽

Hospital Length ◽

Adult Patients ◽

Drotrecogin Alfa Activated

Download Full-text

Eli Lilly has announced the withdrawal of Xigris [drotrecogin alfa] in all markets based on trial results

Reactions Weekly ◽

10.2165/00128415-201113760-00004 ◽

2011 ◽

Vol &NA; (1376) ◽

pp. 2

Author(s):

&NA;

Keyword(s):

Drotrecogin Alfa

Download Full-text